A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping | MicrobiomeTrials
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-09-01Est. Completion: 2029-05
Enrollment target: 70 participants
Locations
UZ Leuven, Leuven, Belgium
Centre Hospitalier Régional de la Citadelle, Liège, Belgium